Researchers have found in a new study that the novel Lesifter device shows encouraging early efficacy and a favorable safety profile in reducing stroke risk among patients with atrial ...

In the PROTECT AF trial, patients randomized to left atrial appendage closure initially continued taking warfarin and aspirin to promote device endothelialization. At 45 days after the procedure, 86.8 ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient treated with PerQseal ® ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

(RTTNews) - Shares of Catheter Precision Inc. (VTAK) are up over 65% at $4.36, following an encouraging regulatory news related to its LockeT wound closure device. LockeT is a suture retention device ...